夜間視覺障礙(NVD)- 市場洞察，流行病學，預測 2028年
Night Vision Disturbances Market Insights, Epidemiology and Market Forecast - 2028
|出版商||DelveInsight Business Research LLP||商品編碼||918180|
|出版日期||內容資訊||英文 45 Pages
|夜間視覺障礙(NVD)- 市場洞察，流行病學，預測 2028年 Night Vision Disturbances Market Insights, Epidemiology and Market Forecast - 2028|
|出版日期: 2019年12月01日||內容資訊: 英文 45 Pages||
DelveInsight's 'Night Vision Disturbances (NVD)- Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of NVDs in the United States.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Night Vision Disturbances (NVD) from 2017 to 2028 in the United States. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Study Period: 2017-2028
Night Vision Disturbances (NVD) means difficulty (i.e. poor or inability) to see in dark conditions and it is harder and takes longer time to adjust and visualize when there is a change from well-lighted conditions to darkness. Bright circles that surround the light source are known as hallos whereas difficulty in seeing due to a direct or reflected bright light is known as glare.
The DelveInsight Night Vision Disturbances (NVD) market report gives the thorough understanding of the Night Vision Disturbances by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Night Vision Disturbances in the US, Europe and Japan.
The Night Vision Disturbances (NVD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident Cases of NVD in the United States, Incident cases of NVD by Type of Surgeries, Incidence of NVD Manifestations) scenario of Night Vision Disturbances (NVD)in the United States from 2017-2028.
According to DelveInsight, the total number of Incident cases of Night Vision Disturbances (NVD) in 7 MM was found to be 3,392,937 in the year 2017.
This segment of the Night Vision Disturbances report encloses the detailed analysis of late stage (Phase-II) drug, Nyxol. Nyxol (Lynx-1) is a novel eye drop treatment for multiple front-of-the-eye disorders, including night vision disturbances (NVD). This segment also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The Night Vision Disturbances market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of Nyxol by evaluating its impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Night Vision Disturbances in the US was found to be USD 761 Million in 2017, and is expected to increase during the course of the study period (2017-2028).
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Note: We understand the needs of the rapidly changing market and DelveInsight's is helping the client by providing the most up to date Report. It usually takes 24 Hours to deliver this kind of Report.